Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland

Conclusions This study, the first of its kind from Ireland where CF prevalence is highest, does not provide unequivocal support for prophylactic use of palivizumab in CF patients under 2 years. Despite being derived from a small sample size, based on these data and complementary clinical observation, we have discontinued such prophylaxis. However, should reported incidence of RSV-related hospitalisation increase, there is scientific plausibility for appropriately powered, randomised, controlled trials of palivizumab.
Source: Multidisciplinary Respiratory Medicine - Category: Respiratory Medicine Source Type: research